Market Overview

Corindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention Symposium


Educational Activities will Highlight CorPath GRX Capabilities in PVI

Vascular Robotics
, Inc. (NYSE:CVRS), a leading developer
of precision vascular robotics, announced today that the CorPath GRX
System will be showcased for peripheral applications at the 2018
Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D.,
Interventional Cardiologist and AMP course director, will moderate an
educational session entitled "Robotic Utilization in CLI in 2018:
Protect Your Staff, Protect Yourself" on Friday, August 10th
at 4:00 p.m. CT. During this session, Dr. Mustapha will share and
discuss a previously taped procedure in which he used the CorPath GRX
System during a robotic-assisted critical limb ischemia (CLI) case he
performed at the first U.S. outpatient CLI center, the Advanced Cardiac
& Vascular Amputation Prevention Center in Grand Rapids, MI, which was
opened by Dr. Mustapha and Dr. Fadi Saab in February 2018.

"CorPath GRX offers discrete movements with precise control of
interventional devices, offering advanced treatment options for patients
suffering from CLI while reducing physician fatigue," said Dr. Jihad
Mustapha. "I believe robotics will enable physicians to perform more CLI
procedures and will be a critical component to the future treatment
paradigm for limb salvage patients. I look forward to educating my peers
and the CLI community on my experience with robotic-assisted CLI."

Corindus will feature robotic-assisted peripheral vascular intervention
(PVI) in Pavilion B with an opportunity for attendees to experience
hands-on demonstrations of the CorPath GRX System with an advanced
simulator. During exhibit hours, the Corindus Research and Development
team will host a Next-Generation Robotics Showcase in Pavilion B for
physicians to participate in development initiatives to capture manual
device manipulation data. This data will help support the advancement of
current robotic capabilities as well as feed into future technology
advancements. AMP attendees are invited to pre-register for a
demonstration and the Next-Generation Robotics Showcase by visiting

Corindus received 510(k) clearance for use of its CorPath GRX System in
peripheral procedures in February 2018, broadening the capabilities of
the CorPath robotic technology platform from exclusively treating
coronary artery disease (CAD) to include peripheral artery disease
(PAD), a disease of blood vessels outside the heart that commonly
affects arteries carrying blood to the lower extremities. Critical limb
ischemia (CLI), a form of PAD, is associated with excessively high risk
for cardiovascular events, including myocardial infarction, and death.
Mortality rates following diagnosis of CLI are as high as 20% after 6
months and 50% after 5 years.1 It is estimated that total
hospital costs associated with lower-extremity amputation exceed the
cost of revascularization by approximately $10,000.2

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in
robotic-assisted vascular interventions. The company's CorPath® System
is the first FDA-cleared medical device to bring robotic precision to
percutaneous coronary and percutaneous vascular procedures. During the
procedure, the interventional cardiologist sits at a radiation-shielded
workstation to advance guide catheters, stents, and guidewires with
millimeter-by-millimeter precision. The workstation allows the physician
greater control and the freedom from wearing heavy lead protective
equipment that causes musculoskeletal injuries. CorPath GRX is the
second generation robotic-assisted PCI technology offering enhancements
to the platform by adding important key upgrades that increase
precision, improve workflow, and extend the capabilities and range of
procedures that can be performed robotically. With the CorPath System,
Corindus Vascular Robotics brings robotic precision to interventional
procedures to help optimize clinical outcomes and minimize the costs
associated with complications of improper stent placement during manual
procedures. Corindus stands behind its product with its unique $1,000
hospital credit "One Stent Program." For additional information, visit,
and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical
or current facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects," "estimates,"
"intends," "anticipates" or "plans" to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus' beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus' control.

Examples of such statements include statements regarding or such as:

  • That CorPath GRX offers advanced treatment options for patients
    suffering from CLI while reducing physician fatigue;
  • that robotics will enable physicians to perform more CLI procedures
    and will be a critical component to the future treatment paradigm for
    limb salvage patients; and
  • that the data collected from physicians participating in
    Next-Generation Robotics Showcase will help support the advancement of
    current robotic capabilities as well as feed into future technology

Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described in the sections titled "Risk Factors" in the Company's filings
with the Securities and Exchange Commission, including its most recent
Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as
well as reports on Form 8-K, including, but not limited to the
following: our ability to expand our technology platform and achieve the
advances necessary for telestenting and remote procedures, including in
humans; our ability to expand our technology platform for use in other
segments of the vascular intervention market, including
neurointerventional and other more complex cardiac interventions;
obtaining necessary regulatory approvals for the use on humans and
marketing of our products in the United States and in other countries;
risks associated with market acceptance; our ability to enforce our
intellectual property rights; our need for additional funds to support
our operations; factors relating to engineering, regulatory,
manufacturing, sales and customer service challenges; and potential
safety and regulatory issues that could slow or suspend our sales.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus' website at

1 Critical Limb Ischemia: Current Trends and Future Directions. Martin
Teraa, Michael S. Conte, Frans L. Moll, Marianne C. Verhaar. J Am Heart
Assoc. 2016 Feb; 5(2): e002938. Published online 2016 Feb 23. doi:
10.1161/JAHA.115.002938 PMCID: PMC4802465.

2 Decision Resources Group

View Comments and Join the Discussion!